241PD BEECH: a randomised phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
Turner, N Alarcón, E Armstrong, Anne C Philco, M López Chuken, Y Sablin, M-P Tamura, K Gomez Villanueva, A Pérez-Fidalgo, J Foxley, A
Turner, N
Alarcón, E
Armstrong, Anne C
Philco, M
López Chuken, Y
Sablin, M-P
Tamura, K
Gomez Villanueva, A
Pérez-Fidalgo, J
Foxley, A
Citations
Altmetric:
Abstract
Description
Date
2017-09
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
241PD BEECH: a randomised phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. 2017, 28(suppl_5): Ann Oncol